Bifogade filer
Targinta obtains patent grant in Japan
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), announces that the Japanese Patent Office (JPO) has granted a patent covering treatment of tumors of the central nervous system (CNS) using antibodies targeting integrin α10β1. The patent further strengthens Targinta’s intellectual property position and coverage for drug development candidates TARG9 and TARG10.
Targinta’s patent family entitled “Detection and treatment of malignant tumours in the CNS” comprises granted patents in the United States, Europe and Australia, and has now, following the grant by the JPO, granted patents in a large part of the key markets. The Japanese patent protects integrin α10β1-targeting products for treatment of CNS tumors such as glioblastoma until 2036, thus securing market exclusivity for Targinta’s lead candidates TARG9 and TARG10.
"We are very pleased with the grant of the patent in Japan which together with previous grants in the US, Europe and Australia protects our drug development pipeline for many years to come. With a unique target overexpressed in several aggressive cancers and a comprehensive patent protection, Targinta stands very strong and sees great potential to enter early partnerships to accelerate the development of our new cancer treatments to patients”, says Targinta's CEO Per Norlén.
For further information please contact:
Per Norlén, CEO Targinta AB
E-mail: per.norlen@targinta.se
Phone: 046-275 65 00
About Targinta AB
Targinta is a preclinical oncology company developing tumor-targeting antibodies and ADCs based on the in-house discovery of the unique target integrin α10β1 that is overexpressed in aggressive cancers like triple-negative breast cancer and glioblastoma. The pipeline consists of TARG10, a function-blocking integrin α10-antibody that counteracts metastasis, and TARG9, a toxin-conjugated α10-antibody (ADC) that acts by direct killing of tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) headquartered in Lund, Sweden. For further information please refer to www.targinta.se.
About Xintela AB
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.